C. Michael Gibson, MD
Beth Israel Deaconess Medicine Center, Boston, Mass.
|ATLAS ACS 2- TIMI 51|
Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome
Discussant: Paul W. Armstrong, MD, FAHA, Edmonton, AB, Canada
|LBCT.02 - Mon., Nov. 14, 10:45 a.m.|
Niteesh K. Choudhry,
Harvard Medical School, Boston, Mass.
|Post-MI FREEE |
The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial
Discussant: Eric D. Peterson, MD, MPH, FAHA, Durham, N.C.
MD, MPH, FAHA
Mid America Heart Institute, Kansas City, Mo.
|Evidence-Based, Individualized Informed Consent Form |
Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients' Experiences with PCI
Discussant: Manesh R. Patel, MD, Durham, N.C.
|LBCT.03 - Mon., Nov. 14, 3:45 p.m.|
Peter R. Kowey, MD
MLH Heart Center Lankenau Medical Center,
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE)
Discussant: Cynthia M. Tracy, MD, FAHA, Washington, D.C.
Stuart J. Connolly, MD
Hamilton General Hospital, Hamilton, ON, Canada
The Results of the PALLAS Study: PALLAS was designed to test whether dronedarone could reduce major vascular morbidity and mortality in patients with permanent atrial fibrillation and previous vascular disease or multiple risk factors.
Discussant: Mark Estes III, MD, FAHA, Boston, Mass.
|LBCT.04 - Tues., Nov. 15, 10:45 a.m.|
William E. Boden, MD, FAHA
University of Buffalo,
Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial
Discussant: Philip Barter, MD, PhD, Sydney Nsw, Australia
|LBCT.05 - Wed., Nov. 16, 10:45 a.m.|
Duk-Hyun Kang, MD, PhD
Asan Medical Ctr, Seoul, Korea, Republic of
Randomized Trial of Early Surgery versus Conventional Treatment for Infective Endocarditis (EASE)
Discussant: Robert S. Higgins, MD, Columbus, Ohio
Roberto Bolli, MD, FAHA
University of Louisville,
Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial